chronic bronchitis
Conditions
Interventions
Test group:Guben Kechuan granules, 3 times a day, 1 bag each time (2G / bag)
Blank control group:Patient education
Positive drug control group:Guilong Kechuanning capsule, 3 capsules each time, 3 times a day
Sponsors
CHINA-JAPAN FRIENDSHIP HOSPITAL
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Consistent with the diagnosis of chronic bronchitis; (2) The scores of main symptoms of chronic bronchitis (cough, expectoration and wheezing) were all = 1 point; (3) Age 18-75 years old (including 18 and 75 years old), gender is not limited; (4) Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Acute bronchitis or acute exacerbation of chronic bronchitis in recent 1 month; (2) Pulmonary tuberculosis, eosinophilic bronchitis, bronchial lung cancer, idiopathic pulmonary fibrosis, pneumonia, bronchial asthma, bronchiectasis, gastroesophageal reflux and other diseases with cough, expectoration or wheezing symptoms; (3) Have taken drugs similar to the functional indications of the test drug in the past 2 weeks; (4) SCR of renal function is greater than the upper limit of reference value or ALT and AST of liver function are more than 2 times of the upper limit of reference value; (5) Complicated with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney, digestive and hematopoietic system; (6) Have a long history of alcohol and drug abuse; (7) Pregnant and lactating women and during the trial cannot be strictly contraception; (8) Have a history of allergy to test drug components; (9) Having intellectual disability or mental disorder; (10) Participated in other clinical trials in the past 3 months; (11) The investigator considers it inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| immunity;Symptom evaluation of chronic bronchitis (cough, expectoration, wheezing);AECB;Inflammatory factor;Pulmonary function;EQ5D; | — |
Countries
China
Contacts
Public ContactDaowen Yang
Outcome results
None listed